Cangrelor

Sharing is caring!

Cangrelor Brand Name– Kengreal

What is Cangrelor

Cangrelor is an injectable P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not receiving a glycoprotein IIb/IIIa inhibitor.

Cangrelor is the only injectable P2Y12 inhibitor and is only administered during PCI. Following PCI, patients are transitioned to an oral P2Y12 inhibitor. Platelet inhibition occurs within 2 minutes of drug administration and returns to normal within 1 hour of discontinuation.

Cangrelor was approved by the FDA in June 2015.

Indications

  • myocardial infarction prophylaxis
  • percutaneous coronary intervention (PCI)

For use as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (i.e., myocardial infarction prophylaxis), repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

Side Effects

  1. anaphylactic shock
  2. anaphylactoid reactions
  3. angioedema
  4. bleeding
  5. bleeding
  6. bleeding
  7. bronchospasm
  8. dyspnea
  9. ecchymosis
  10. GI bleeding
  11. hematoma
  12. hematuria
  13. intracranial bleeding
  14. retroperitoneal bleeding
  15. wheezing

Monitoring Parameters

  • hemoglobin/hematocrit

Contraindications

  • bleeding
  • breast-feeding
  • children
  • infants
  • labor
  • obstetric delivery
  • pregnancy
  • renal impairment

Interactions

  • Clopidogrel
  • Defibrotide
  • Prasugrel
  • Selective serotonin reuptake inhibitors

Sharing is caring!

15585

Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

15856